G 1/26 amicus curiae briefs: the 30 November deadline and whether to file

Third parties have until 30 November 2026 to file a G 1/26 amicus curiae brief with the EPO’s Enlarged Board of Appeal, which is deciding how claims must be read when an amendment is checked for added matter. Any company, industry association or SME that drafts, amends or opposes European patents may file, in English, French or German. This guide sets out the positions on the table and helps you decide whether a brief, or a change in drafting practice, is the better use of your time.

Key takeaways

  • The deadline for written statements is 30 November 2026, set in the Official Journal communication OJ EPO 2026, A37.
  • In early October 2026 the Enlarged Board’s page listed a single brief, filed on 4 September 2026 by European patent attorney Michael Schmid.
  • Boards of Appeal currently follow three different approaches to reading a claim for added matter; G 1/26 will choose between them or set a new test.
  • A brief adds most value when it brings practical evidence from a sector or filing route, not when it repeats doctrinal arguments already made.
  • Whatever the answer, claims that define their own units and key terms remain the safest position.

What is the Enlarged Board deciding in G 1/26?

The referral comes from Technical Board of Appeal 3.3.05 in case T 873/24, an opposition appeal over a patent for coated steel strips. The granted claim gives a ratio of titanium to nitrogen without saying whether it is a weight or a molar ratio, and only one reading has a clear basis in the application as filed. The referring decision asks three sets of questions:

  • Question 1 (admissibility): when is a decision of the Enlarged Board “required” under Article 112(1) EPC, if the point arises from the case and it is reasonable for the Board to decide it next?
  • Question 2 (claim interpretation): can a feature disclosed only in the description or drawings be read into a granted claim, especially to narrow it, or is interpretation one unitary exercise of claims and description together?
  • Question 3 (added matter, Article 123(2) EPC): must a claim term be tested against every technically sensible reading of the claim alone, or only against the reading established from the patent as a whole?

The background is G 1/24 (18 June 2025), which held that the description and drawings must always be consulted to interpret the claims when assessing patentability under Articles 52 to 57 EPC. It did not say whether the same applies to added matter, and that is the gap G 1/26 is meant to close.

Which positions have been put forward so far?

Commentators describe three lines of case law since G 1/24. Appleyard Lees (8 June 2026) summarises them as follows:

Approach Role of the description Practical effect on amendments
1. Claim read on its own Context only: field and skilled person Every technically sensible reading of an ambiguous term must have a basis in the application; strictest for patentees
2. Middle ground Rules out readings that contradict it, but cannot add limitations Ambiguity is narrowed only where the description excludes a reading
3. Holistic reading Claims read as part of the whole specification, broader or narrower The meaning established from the patent as a whole is what must be supported

The only brief on file in early October, by Michael Schmid (4 September 2026), argues for a version of the third approach. In summary, it proposes answering Question 1 yes, Question 2(a) no and Question 3(a) no: definitions and explanations in the description may shape the meaning of a claim term, provided the claimed feature keeps its technical identity, and the same meaning should apply to patentability and to added matter. It also warns that an applicant should not rely on a narrow meaning taken from the description during examination while keeping broader wording in the claim; the limitation belongs in the claim.

Not everyone expects the Enlarged Board to go that far. Writing for Reddie & Grose (24 June 2026), Nick Reeve considers it unlikely, given existing case law, that limitations found only in the description will defend an amendment against an added matter objection. More briefs usually arrive close to the deadline, so the balance of views may look different by 30 November.

Should your company file a G 1/26 amicus curiae brief?

A brief is public, takes time to prepare well and does not make you a party to the case: the Enlarged Board decides how far to take it into account. It is worth the effort when you can add something the Board would not otherwise hear. A rough guide:

Your profile A brief makes sense when… Often a better use of time
Industry or professional association Members share a drafting practice (parameters, ranges, ratios) that one answer would put at risk A coordinated brief rather than many individual ones
Applicant with a large European portfolio You can show, anonymised, how each approach changes the fate of typical amendments Supporting your association’s brief
Frequent opponent A strict test matters to your opposition strategy Reviewing pending oppositions for interpretation arguments
SME with a few European filings Rarely; the cost is high relative to the influence Auditing claim wording in your key families
Applicant entering Europe via the PCT from Latin America or Africa An association can explain how translated priority texts create ambiguity Checking translations before European phase entry

If you do file, the A37 communication sets the formalities: a written statement under Article 10 of the Enlarged Board’s Rules of Procedure, in an official EPO language, sent to the Registry of the Enlarged Board quoting case number G 1/26, by 30 November 2026. Answer the questions as referred, keep each point short and support it with concrete, anonymised examples. Briefs received are published on the pending referrals page, so nothing confidential should go in.

What this means for your business

  1. Decide by mid-November whether you or your association will file; a rushed brief adds little.
  2. List the families that rely on parameters, ratios or terms defined only in the description, and rank them by commercial value.
  3. For pending applications, consider putting key definitions into the claims now, while there is still a clear basis in the application as filed.
  4. For granted patents facing opposition, prepare arguments that work under both a strict and a holistic reading.
  5. For new filings, state units, bases and measuring methods in the claims and use defined terms consistently, including in translations.

Our team handling European patent drafting, prosecution and oppositions can review those families against the three approaches and tell you where an amendment would be vulnerable.

Where companies get this wrong

  • Treating the brief as a lobbying letter. The Board answers legal questions; examples and reasoning carry weight, general preferences do not.
  • Including confidential claim strategy, forgetting that briefs are published.
  • Waiting for the decision before reviewing anything. The EPO has said it will promptly apply the outcome in examination and opposition, so existing patents will be judged by it too.
  • Relying on the description to rescue the claim. Even the brief most favourable to patentees says the limitation should be in the claim.
  • Letting different advisers handle the priority text, the PCT translation and the European amendments, so terminology drifts across the family.

Frequently asked questions

What is an amicus curiae brief in G 1/26?

It is a written statement from someone who is not a party to the case, filed to help the Enlarged Board answer the referred questions. In G 1/26 the EPO invited such statements in OJ EPO 2026, A37. They are published on the Board’s pending referrals page, and the Board decides how far to take them into account.

Who can file, and by when?

Any third party: companies, associations, professional bodies or individual practitioners. The statement must be filed by 30 November 2026 with the Registry of the Enlarged Board of Appeal, quoting case number G 1/26, in English, French or German, as set out in the Official Journal communication of 31 July 2026.

Does G 1/26 stop examination or oppositions at the EPO?

No. The EPO announced on 11 June 2026 that examination and opposition proceedings continue while the referral is pending, as they did during G 1/24 and G 1/25. Examining and opposition divisions keep applying the current Guidelines until the Enlarged Board decides.

Can IP Global Guard help us prepare a brief or adapt our drafting?

Yes. We prepare and coordinate the work with European patent attorneys, review your key families against the competing approaches and, if a brief makes sense, help structure the arguments and examples. For families that start in Latin America or Africa, we also check the priority texts and translations from a single point of contact.

How IP Global Guard can help before 30 November

G 1/26 will decide how much the description can help a claim that is ambiguous on its own. Whether or not you file a brief, the useful work is the same: find the families that depend on that answer and fix what can still be fixed. IP Global Guard, the IP services line of META Channel Corporation Limited, coordinates patent families across more than 25 jurisdictions in Europe, Latin America and Africa with one strategy and one billing relationship.

Send us the families that matter most and the stage each one is at. We will flag the claims most exposed to G 1/26 and, if you want to file, tell you what a brief could usefully add. Talk to our patent team.

This article is general information, not legal advice, and reflects the position known when it was prepared.

Sources

Share